Ivey Chair in Molecular Toxicology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
J Clin Pharmacol. 2013 Jun;53(6):626-32. doi: 10.1002/jcph.85. Epub 2013 May 14.
Drug hypersensitivity reactions (DHRs) are rare but potentially fatal adverse drug reactions (ADRs). A reliable test to diagnose DHRs would be a major advance in the clinical care for patients and in the evaluation of ADRs during drug development as well as for mechanistic studies of drug hypersensitivity. Available in vitro tests including the lymphocyte toxicity assay (LTA) have been used but are time-consuming, cumbersome, and expensive. We have developed a novel diagnostic test for DHRs, the in vitro platelet toxicity assay (iPTA). The aim of this study was to evaluate the predictive value of the iPTA in diagnosis of DHRs to sulfonamides. We recruited 66 individuals (36 DHS-sulfa patients and 30 healthy controls) to participate in the study. Blood samples were obtained and LTA and iPTA were performed in parallel. There was concentration-dependent toxicity in the cells of patients when incubated with the reactive hydroxylamine metabolite of sulfamethoxazole for both the LTA and iPTA (P < .05). The iPTA was more sensitive than conventional LTA test in detecting susceptibility of patient cells to in vitro toxicity (P < .05). The novel iPTA has considerable potential as an investigative tool for DHS as it is more sensitive and cheaper, requiring no special reagents.
药物过敏反应(DHRs)较为罕见,但却可能致命。可靠的 DHR 诊断测试将是患者临床护理、药物开发期间不良反应评估以及药物过敏机制研究的重大进展。现有的体外测试,包括淋巴细胞毒性测定(LTA)已经被应用,但这些测试耗时、繁琐且昂贵。我们开发了一种新的 DHR 诊断测试,即体外血小板毒性测定(iPTA)。本研究旨在评估 iPTA 对磺胺类药物 DHR 诊断的预测价值。我们招募了 66 名个体(36 名 DHS-磺胺患者和 30 名健康对照者)参与研究。采集血样并同时进行 LTA 和 iPTA 测试。对于 LTA 和 iPTA,与磺胺甲恶唑的反应性羟胺代谢物孵育时,患者细胞具有浓度依赖性毒性(P <.05)。与传统的 LTA 测试相比,iPTA 在检测患者细胞对体外毒性的敏感性方面更具优势(P <.05)。新型 iPTA 具有作为 DHS 研究的有潜力的调查工具,因为它更灵敏且更便宜,不需要特殊试剂。